phase II study of vindesine in patients with hodgkin's disease, lymphoma, and breast cancer

Seventy-four patients with Hodgkin's disease, lymphomas, and breast cancer were treated with vindesine 3 mg - 3.5mg/ m/[2]/week iv. Complete, partial and mixed responses were encountered in 16 of 26 patients with Hodgkins disease, in 9 of 24 lymphoma patients, and partial response in 4 of 24 breast cancer patients. Mild to moderate degree of peripheral neuropathy was encountered in 46 patients. Mild leucopenia was seen in 12 patients. It is concluded that vindesine is efficacious in Hodgkin's disease and lymphomas, and is recommended for combination chemotherapy regimes